White Pine Capital LLC acquired a new position in shares of Codexis, Inc. (NASDAQ:CDXS) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 50,800 shares of the biotechnology company’s stock, valued at approximately $277,000. White Pine Capital LLC owned about 0.11% of Codexis at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Prescott Group Capital Management L.L.C. lifted its stake in Codexis by 607.8% during the second quarter. Prescott Group Capital Management L.L.C. now owns 2,040,324 shares of the biotechnology company’s stock worth $11,120,000 after purchasing an additional 1,752,049 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Codexis by 23.3% during the second quarter. Baillie Gifford & Co. now owns 1,461,413 shares of the biotechnology company’s stock worth $7,965,000 after purchasing an additional 276,280 shares during the last quarter. William Blair Investment Management LLC lifted its stake in Codexis by 10.5% during the second quarter. William Blair Investment Management LLC now owns 1,090,072 shares of the biotechnology company’s stock worth $5,941,000 after purchasing an additional 103,233 shares during the last quarter. Essex Investment Management Co. LLC lifted its stake in Codexis by 40.1% during the second quarter. Essex Investment Management Co. LLC now owns 288,876 shares of the biotechnology company’s stock worth $1,574,000 after purchasing an additional 82,738 shares during the last quarter. Finally, Blair William & Co. IL lifted its stake in Codexis by 61.6% during the second quarter. Blair William & Co. IL now owns 279,797 shares of the biotechnology company’s stock worth $1,525,000 after purchasing an additional 106,700 shares during the last quarter. Hedge funds and other institutional investors own 63.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “White Pine Capital LLC Invests $277,000 in Codexis, Inc. (CDXS) Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/11/white-pine-capital-llc-invests-277000-in-codexis-inc-cdxs-stock.html.

Several equities analysts recently issued reports on the company. BidaskClub cut Codexis from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded Codexis from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a research note on Wednesday, July 19th. ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, HC Wainwright set a $8.00 price objective on Codexis and gave the stock a “buy” rating in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $6.80.

Codexis, Inc. (NASDAQ CDXS) traded up 0.446% during midday trading on Monday, reaching $5.625. The company’s stock had a trading volume of 3,739 shares. The firm has a 50 day moving average price of $5.38 and a 200 day moving average price of $4.83. The firm’s market capitalization is $271.82 million. Codexis, Inc. has a 1-year low of $3.60 and a 1-year high of $5.75.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The business had revenue of $10.30 million for the quarter, compared to analysts’ expectations of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. Codexis’s quarterly revenue was down 35.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 earnings per share. On average, analysts predict that Codexis, Inc. will post ($0.38) EPS for the current year.

Codexis Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Stock Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related stocks with our FREE daily email newsletter.